Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbbVie Inc.
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?
Democrats gain majority on Federal Trade Commission with Bedoya’s swearing in. His positions on technology and digital privacy suggest he will align with commissioners who have advocated stricter review of pharma mergers.
- Other Names / Subsidiaries
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA